IRIS PubliCatt

Pera, Maria Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.767
EU - Europa 1.337
AS - Asia 226
AF - Africa 19
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 3.366
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.743
IT - Italia 380
SE - Svezia 373
IE - Irlanda 194
CN - Cina 76
DE - Germania 74
FR - Francia 74
IN - India 59
GB - Regno Unito 44
FI - Finlandia 24
RU - Federazione Russa 23
UA - Ucraina 19
IR - Iran 17
ES - Italia 15
BE - Belgio 14
NL - Olanda 13
RO - Romania 13
MK - Macedonia 12
CH - Svizzera 11
HK - Hong Kong 11
IL - Israele 11
CA - Canada 10
CI - Costa d'Avorio 10
PA - Panama 10
CZ - Repubblica Ceca 9
JP - Giappone 9
RS - Serbia 9
SG - Singapore 9
PT - Portogallo 8
BR - Brasile 7
TR - Turchia 7
EG - Egitto 6
KR - Corea 6
HR - Croazia 5
PL - Polonia 4
SK - Slovacchia (Repubblica Slovacca) 4
AT - Austria 3
BD - Bangladesh 3
CO - Colombia 3
DK - Danimarca 3
MX - Messico 3
PH - Filippine 3
BT - Bhutan 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
TW - Taiwan 2
VN - Vietnam 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
AU - Australia 1
BG - Bulgaria 1
CL - Cile 1
GL - Groenlandia 1
HU - Ungheria 1
LK - Sri Lanka 1
MT - Malta 1
MY - Malesia 1
OM - Oman 1
PE - Perù 1
QA - Qatar 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.366
Salva come PNG Salva come JPEG
Città #
Chandler 460
Ashburn 296
Dublin 175
New York 131
Rome 97
Milan 70
Marseille 44
Boston 38
San Mateo 38
Princeton 36
Pune 33
Los Angeles 27
Ann Arbor 21
Dearborn 19
Wilmington 19
Chicago 18
Nanjing 18
Bremen 17
Palermo 17
Helsinki 14
Seattle 12
Jacksonville 11
Redwood City 11
Abidjan 10
Andover 10
Brussels 10
Houston 10
Skopje 10
Cattolica 9
Kish 9
London 9
Augusta 8
Boardman 8
Edinburgh 8
Fairfield 8
Paris 8
Washington 8
Amsterdam 7
Bari 7
Brno 7
Lancaster 7
Madrid 7
Redmond 7
Toronto 7
Hong Kong 6
Jiaxing 6
Menlo Park 6
Niš 6
Shanghai 6
Shenyang 6
Beijing 5
Busto Arsizio 5
Cairo 5
Hebei 5
Hyderabad 5
Lawrence 5
Leawood 5
Lisbon 5
Mountain View 5
Norwalk 5
Seoul 5
São Paulo 5
Zagreb 5
Barcelona 4
Bitonto 4
Bologna 4
Cambridge 4
Changsha 4
Fort Worth 4
Genoa 4
Giugliano in Campania 4
Jinan 4
Monza 4
Naaldwijk 4
San Francisco 4
Secaucus 4
Turin 4
Viterbo 4
Bern 3
Bucaramanga 3
Caorle 3
Chieti 3
Dhaka 3
Frankfurt am Main 3
Grottaferrata 3
Hangzhou 3
Izmir 3
Krakow 3
Kunming 3
Nanchang 3
Neded 3
Ronciglione 3
San Diego 3
Spoleto 3
Trieste 3
West Chester 3
Woodbridge 3
Adelfia 2
Ancona 2
Ankara 2
Totale 2.020
Salva come PNG Salva come JPEG
Nome #
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 100
Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standars of Care? 93
Revised upper limb module for spinal muscular atrophy: Development of a new module 92
Predominant distal muscle involvement in spinal muscular atrophy 76
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 74
Developmental milestones in type I spinal muscular atrophy 72
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 66
Developmental milestones in type I spinal muscular atrophy 64
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 64
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 62
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 62
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 61
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 60
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 60
Predictive models in SMA II natural history trajectories using machine learning: A proof of concept study 59
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 58
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 58
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 57
6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction 55
Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. 52
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 52
The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure 52
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 52
SMA-miRs (MiR-181a- 5p, -324-5p, and -451a) are overexpressed in spinal muscular atrophy skeletal muscle and serum samples 52
Assessing floppy infants: a new module 52
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 50
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 49
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 49
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 47
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 47
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 47
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 46
Clinical Variability in Spinal Muscular Atrophy Type III. 46
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 45
Development of an academic disease registry for spinal muscular atrophy 45
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 44
Body mass index in type 2 spinal muscular atrophy: a longitudinal study 42
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 41
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 40
Gain and loss of abilities in type II SMA: A 12-month natural history study 39
1st Italian SMA Family Association Consensus Meeting: Management and recommendations for respiratory involvement in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30-31 January 2015 38
Revised upper limb module for spinal muscular atrophy: 12 month changes 38
Age and baseline values predict 12 and 24-month functional changes in type 2 SMA 36
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial 35
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 35
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 34
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 34
Spinal muscular atrophy — insights and challenges in the treatment era 34
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 33
Revised upper limb module for spinal muscular atrophy: Development of a new module 33
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 33
Longitudinal natural history of type I spinal muscular atrophy: A critical review 33
Risdiplam in Type 1 Spinal Muscular Atrophy 32
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 32
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 31
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 31
Sleep disorders in spinal muscular atrophy 29
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 29
Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials 28
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 26
Old measures and new scores in spinal muscular atrophy patients 26
Long-term evolution of neuropsychological competences in encephalopathy with status epilepticus during sleep: a variable prognosis 24
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis 22
Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment 22
An observational study of functional abilities in infants, children, and adults with type 1 SMA 21
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 20
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy 19
Epileptic Encephalopathies with Status Epilepticus during Sleep: New Techniques for Understanding Pathophysiology and Therapeutic Options 19
Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children 18
Neonatal hypotonia and neuromuscular conditions 18
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Early neurodevelopmental assessment in Duchenne muscular dystrophy 18
Long term follow-up of scoliosis progression in type II SMA patients 17
Cognitive impairment in paediatric multiple sclerosis patients is not related to cortical lesions 17
An observational study of functional abilities in infants, children, and adults with type 1 SMA 17
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage 17
Risdiplam in Type 1 Spinal Muscular Atrophy 17
Paediatric optic neuritis: factors leading to unfavourable outcome and relapses 17
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 15
New therapies for spinal muscular atrophy: where we stand and what is next 15
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 15
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy 14
Regional hippocampal involvement and cognitive impairment in pediatric multiple sclerosis 14
Therapy of encephalopathy with status epilepticus during sleep (ESES/CSWS syndrome): an update 13
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 12
SFP CO-31 - Inflammatory optic neuritis: Course and prognostic factors in 102 children|SFP CO-31 - Névrites optiques inflammatoires: évolution et facteurs pronostiques chez 102 enfants 11
Development of an academic disease registry for spinal muscular atrophy 9
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 8
MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients 8
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 6
How to Manage Electrical Status Epilepticus in Sleep 6
Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy 4
Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey 3
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 3
Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? 2
Early treatment of type II SMA slows rate of progression of scoliosis 2
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 2
Totale 3.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.198
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201930 0 0 0 0 0 0 0 0 0 0 9 21
2019/2020101 25 1 1 3 5 15 16 3 1 4 23 4
2020/202170 2 6 1 3 5 7 8 1 12 5 18 2
2021/2022449 30 6 5 63 34 13 9 63 33 27 70 96
2022/20231.624 108 174 108 222 108 201 102 166 247 36 88 64
2023/20241.059 40 262 48 135 48 239 142 59 18 67 1 0
Totale 3.445